11β-Prostaglandin F_2α ELISA Kit

Prostaglandin D₂ (PGD₂) is the major eicosanoid released from stimulated mast cells. PGD₂ is an unstable compound which is rapidly metabolized and eliminated from the circulation. This makes quantitation of PGD₂ an unreliable indicator of its in vivo production. 11β-PGF_2α is the primary plasma metabolite of PGD₂ in vivo, the levels of which can increase from 6 pg/ml in a normal healthy volunteer to 490 ng/ml in patients with systemic mastocytosis.¹ The normal human urinary excretion of 11β-PGF_2α is about 11 ng/mmol creatinine (~400 ng/24 hr), which is increased nearly 3-fold upon allergen-induced bronchoconstriction in asthmatics.^2,3 Unlike most prostaglandin metabolites, 11β-PGF_2α retains potent biological activity. 11-β-PGF_2α is equipotent to PGF_2α in inducing human bronchial smooth muscle contractions and inhibition of adipose differentiation.^4,5 11β-PGF_2α was also shown to inhibit ADP or thrombin-induced human platelet aggregation at concentrations of 0.14 to 2.8 µM. ⁶ The Cayman 11β-PGF_2α Assay is a competitive assay that provides accurate measurements of 11β-PGF_2α within the range of 1.6-1,000 pg/ml. Inter and intra-assay CV’s of less than 15% can be achieved at most concentrations. This assay allows sensitive detection of 11β-PGF_2α in the most common sample matrix, which is urine. For plasma and other complex sample matrices, we recommend purification of the sample prior to analysis; a purification protocol is included in the kit booklet. Measurements of 11β-PGF_2α in urine using our ELISA gives values in the same range, but slightly higher than those obtained by GC-MS. This appears to be due to measurement of 11β-PGF_2α plus the 2,3-dinor metabolite of 11β-PGF_2α.²

Needed but not supplied: Please download the kit booklet to verify if UltraPure Water (Milli-Q or equivalent) or any other components are needed for this assay.

WARNING This product is not for human or veterinary use.

1. Liston, T.E., and Roberts, L.J., II Transformation of prostaglandin D₂ to 9α,11β-(15S)-trihydroxy-prosta-(5Z,13E)-dien-1-oic acid (9α,11β-prostaglandin F2): A unique biologically active prostaglandin produced enzymatically in vivo in humans. Proc. Natl. Acad. Sci. USA 82(18), 6030-6034 (1985).

2. O'Sullivan, S., Mueller, M.J., Dahlén, S.E., et al. Analyses of prostaglandin D₂ metabolites in urine: Comparison between enzyme immunoassay and negative ion chemical ionization gas chromatography-mass spectrometry. Prostaglandins Other Lipid Mediat. 57(2-3), 149-165 (1999).

3. O'Sullivan, S., Dahlén, B., Dahlén, S.E., et al. Increased urinary excretion of the prostaglandin D₂ metabolite 9α,11β-prostaglandin F2 after aspirin challenge supports mast cell activation in aspirin-induced airway obstruction. J. Allergy Clin. Immunol. 98(2), 421-432 (1996).

4. Coleman, R.A., and Sheldrick, R.L.G. Prostanoid-induced contraction of human bronchial smooth muscle is mediated by TP-receptors. Br. J. Pharmacol. 96(3), 688-692 (1989).

5. Lepak, N.M., and Serrero, G. Inhibition of adipose differentiation by 9α, 11β-prostaglandins F_2α. Prostaglandins 46(6), 511-517 (1993).

6. Pugliese, G., Spokas, E.G., Marcinkiewicz, E., et al. Hepatic transformation of prostaglandin D₂ to a new prostanoid, 9α,11β-prostaglandin F2, that inhibits platelet aggregation and constricts blood vessels. The Journal of Biological Chemisty 260(27), 14621-14625 (1985).